Effettuare il login Iscriviti gratis

SinoMab BioScience Proprietà istituzionale

Cos'è Proprietà istituzionale di SinoMab BioScience?

Proprietà istituzionale di SinoMab BioScience Limited è 21.16%

Qual è la definizione di Proprietà istituzionale?



Proprietà istituzionale (Institutional Ownership) è la quantità di azioni disponibili di una società di proprietà di fondi comuni o pensionistici, compagnie assicurative, società di investimento, fondi o altre grandi entità che gestiscono fondi per conto di terzi.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Proprietà istituzionale di aziende nel Health Care settore su HKSE rispetto a SinoMab BioScience

Cosa fa SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Aziende con proprietà istituzionale simili a SinoMab BioScience